Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bayer Ag S/Adr
(OP:
BAYRY
)
10.91
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bayer Ag S/Adr
< Previous
1
2
3
4
5
6
7
Next >
The Section 122 Pivot: How a 10% Global Tariff is Reshaping the 2026 Market Landscape
March 03, 2026
The global financial markets have entered a period of profound "legalized volatility" following the White House’s emergency invocation of Section 122 of the Trade Act of 1974. This move, triggered by a...
Via
MarketMinute
Topics
Economy
Electric Vehicles
Government
The Strategic Crossroads of FMC Corporation: A 2026 Research Deep Dive
March 03, 2026
Date: March 3, 2026 Introduction FMC Corporation (NYSE: FMC) currently finds itself at one of the most pivotal junctures in its 140-year history. Once a darling of the agricultural sector known for its...
Via
Finterra
Topics
Economy
Intellectual Property
World Trade
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt
↗
November 23, 2025
Via
Stocktwits
The Great Grain Pivot: USDA Forecasts Record Soy Surge as Corn Retreats in 2026
March 02, 2026
The American agricultural landscape is undergoing a massive structural shift as the 2026 planting season approaches. According to the U.S. Department of Agriculture's (USDA) 102nd Agricultural Outlook...
Via
MarketMinute
Topics
Energy
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
February 23, 2026
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...
Via
MarketMinute
Topics
Intellectual Property
Bayer's $7.25 Billion Roundup Settlement: A 21-Year Plan for Certainty
February 18, 2026
Bayer AG (OTC: BAYRY) has announced a sweeping $7.25 billion proposed class action settlement aimed at resolving the vast majority of its remaining U.S. litigation involving the weedkiller Roundup....
Via
MarketMinute
Topics
Lawsuit
Uncle Sam’s $44.36 Per Acre Gamble: How Government Intervention is Distorting the 2026 Planting Season
February 18, 2026
As the 2026 planting season approaches, American farmers are facing a paradox of record-low commodity prices and unprecedented government support. The centerpiece of this intervention is the newly...
Via
MarketMinute
Topics
Economy
German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US
↗
February 18, 2026
Bayer AG (OTC: BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by...
Via
Benzinga
Topics
Lawsuit
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
February 16, 2026
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...
Via
MarketMinute
Wall Street’s ‘Fear Gauge’ Reclaims the 20 Mark: Why the Greenland Tariff Threat and Earnings Redlining Triggered a Market Reset
January 20, 2026
The CBOE Volatility Index (VIX), often hailed as the stock market’s “fear gauge,” surged past the critical 20.00 threshold on January 20, 2026, marking a significant shift in investor sentiment as the...
Via
MarketMinute
Topics
Economy
Government
Stocks
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
January 16, 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Beyond the Bailout: US Farm Groups Demand Structural Reform as USDA Unveils $12 Billion 'Bridge' Program
January 02, 2026
As the 2026 calendar year begins, the United States agricultural sector finds itself at a critical policy crossroads. On one hand, the U.S. Department of Agriculture (USDA) has just finalized the...
Via
MarketMinute
Topics
Economy
Energy
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising
↗
November 20, 2025
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer.
Via
Benzinga
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target
↗
November 14, 2025
Via
Benzinga
Daré Bioscience (DARE) Q3 2025 Earnings Transcript
↗
November 13, 2025
Daré Bioscience (DARE) Q3 2025 Earnings Transcript
Via
The Motley Fool
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks
↗
November 12, 2025
Bayer's Q3 earnings rose on strong Crop Science and Pharma sales, with CEO Bill Anderson confident in meeting the company's upgraded 2025 guidance.
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing In October
↗
October 21, 2025
Via
Benzinga
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
↗
October 20, 2025
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.
Via
Benzinga
Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report
↗
September 15, 2025
Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid falling crop prices and rising costs.
Via
Benzinga
Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal
↗
August 12, 2025
Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, with potential milestone payments of up to $1.3 billion
Via
Stocktwits
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
July 25, 2025
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
July 21, 2025
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...
Via
MarketMinute
Topics
Artificial Intelligence
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
↗
June 23, 2025
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.
Via
Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
↗
June 23, 2025
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.
Via
Investor's Business Daily
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure
↗
May 13, 2025
Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts.
Via
Benzinga
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation
↗
April 10, 2025
Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients.
Via
Benzinga
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish
↗
March 26, 2025
Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very...
Via
Stocktwits
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards
↗
March 05, 2025
Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026.
Via
Benzinga
Topics
Earnings
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
↗
December 17, 2024
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025.
Via
Benzinga
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
↗
November 25, 2024
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
